Literature DB >> 7482228

Are current immunological concepts of multiple sclerosis reflected by the immunopathology of its lesions?

H Lassmann1, K Vass.   

Abstract

Immunopathological studies on multiple sclerosis (MS) brain clearly indicate that a T cell-mediated immune response is the driving force in the induction of the lesions. This T cell-mediated response alone, however, is not sufficient to explain the widespread and selective destruction of myelin sheaths. According to present evidence, it is likely that antibodies directed against surface components of myelin sheaths are at least one factor involved in the demyelinating process. The patterns of inflammation, demyelination and oligodendrocyte destruction, however, suggest that the pathogenesis of the lesions may be fundamentally different in individual MS patients and that autoimmunity may not be the sole cause. In the case of autoimmune reactions various different proteins of the nervous system may become targets and it appears unlikely, that myelin basic protein is a major candidate for a pathogenetic role in MS.

Entities:  

Mesh:

Year:  1995        PMID: 7482228     DOI: 10.1007/bf00194101

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


  54 in total

1.  [Genesis of acute demyelinating encephalitis].

Authors:  F SEITELBERGER; K JELLINGER; H TSCHABITSCHER
Journal:  Wien Klin Wochenschr       Date:  1958-06-20       Impact factor: 1.704

2.  Dual-label immunocytochemistry of the active multiple sclerosis lesion: major histocompatibility complex and activation antigens.

Authors:  T Hayashi; C Morimoto; J S Burks; C Kerr; S L Hauser
Journal:  Ann Neurol       Date:  1988-10       Impact factor: 10.422

Review 3.  Immunology of multiple sclerosis.

Authors:  T Olsson
Journal:  Curr Opin Neurol Neurosurg       Date:  1992-04

4.  Characterization and distribution of phagocytic macrophages in multiple sclerosis plaques.

Authors:  H Li; J Newcombe; N P Groome; M L Cuzner
Journal:  Neuropathol Appl Neurobiol       Date:  1993-06       Impact factor: 8.090

5.  Oligodendrocyte susceptibility to injury by T-cell perforin.

Authors:  N J Scolding; J Jones; D A Compston; B P Morgan
Journal:  Immunology       Date:  1990-05       Impact factor: 7.397

6.  Expression of endothelial cell activation antigens in microvessels from patients with multiple sclerosis.

Authors:  P Dore-Duffy; R Washington; L Dragovic
Journal:  Adv Exp Med Biol       Date:  1993       Impact factor: 2.622

7.  Multiple sclerosis. Oligodendrocyte survival and proliferation in an active established lesion.

Authors:  C S Raine; L Scheinberg; J M Waltz
Journal:  Lab Invest       Date:  1981-12       Impact factor: 5.662

8.  Oligodendrocytes in the early course of multiple sclerosis.

Authors:  W Brück; M Schmied; G Suchanek; Y Brück; H Breitschopf; S Poser; S Piddlesden; H Lassmann
Journal:  Ann Neurol       Date:  1994-01       Impact factor: 10.422

9.  Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system.

Authors:  R A Sobel; M E Mitchell; G Fondren
Journal:  Am J Pathol       Date:  1990-06       Impact factor: 4.307

10.  A study of the chemical nature of components of bovine white matter effective in producing allergic encephalomyelitis in the rabbit.

Authors:  B H WAKSMAN; H PORTER; M D LEES; R D ADAMS; J FOLCH
Journal:  J Exp Med       Date:  1954-11-01       Impact factor: 14.307

View more
  3 in total

Review 1.  Cytokines, signal transduction, and inflammatory demyelination: review and hypothesis.

Authors:  R W Ledeen; G Chakraborty
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

2.  Negative regulation of central nervous system myelination by polysialylated-neural cell adhesion molecule.

Authors:  P Charles; M P Hernandez; B Stankoff; M S Aigrot; C Colin; G Rougon; B Zalc; C Lubetzki
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 3.  The role of alpha-4 integrin in the aetiology of multiple sclerosis: current knowledge and therapeutic implications.

Authors:  William A Sheremata; Alireza Minagar; J Steven Alexander; Timothy Vollmer
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.